Peña-Jiménez, Á.E.; Benitez-Aguilar, O.; Villegas, J.E.; González-de la-Parra, M.; Delgado-Roche, L.
Safety and Effectiveness of Naproxen 220 mg + Paracetamol 300 mg + Pamabrom 25 mg Fixed Dose Combination in Women with Premenstrual Syndrome: A Post-Marketing, Open-Label, Uncontrolled, Prospective, Multicenter, Observational Study. Women 2024, 4, 13-21.
https://doi.org/10.3390/women4010002
AMA Style
Peña-Jiménez ÁE, Benitez-Aguilar O, Villegas JE, González-de la-Parra M, Delgado-Roche L.
Safety and Effectiveness of Naproxen 220 mg + Paracetamol 300 mg + Pamabrom 25 mg Fixed Dose Combination in Women with Premenstrual Syndrome: A Post-Marketing, Open-Label, Uncontrolled, Prospective, Multicenter, Observational Study. Women. 2024; 4(1):13-21.
https://doi.org/10.3390/women4010002
Chicago/Turabian Style
Peña-Jiménez, Álvaro E., Omar Benitez-Aguilar, Jesús E. Villegas, Mario González-de la-Parra, and Livan Delgado-Roche.
2024. "Safety and Effectiveness of Naproxen 220 mg + Paracetamol 300 mg + Pamabrom 25 mg Fixed Dose Combination in Women with Premenstrual Syndrome: A Post-Marketing, Open-Label, Uncontrolled, Prospective, Multicenter, Observational Study" Women 4, no. 1: 13-21.
https://doi.org/10.3390/women4010002
APA Style
Peña-Jiménez, Á. E., Benitez-Aguilar, O., Villegas, J. E., González-de la-Parra, M., & Delgado-Roche, L.
(2024). Safety and Effectiveness of Naproxen 220 mg + Paracetamol 300 mg + Pamabrom 25 mg Fixed Dose Combination in Women with Premenstrual Syndrome: A Post-Marketing, Open-Label, Uncontrolled, Prospective, Multicenter, Observational Study. Women, 4(1), 13-21.
https://doi.org/10.3390/women4010002
